| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/06/2001 | US20010020005 Administering a gastrin inhibitor |
| 09/06/2001 | US20010020004 Wound healing agents, antiulcer agents, vision defects |
| 09/06/2001 | US20010020003 Polypeptides |
| 09/06/2001 | US20010020002 Androgen activity antagonists as therapies for anorexia, anorexia nervosa and disorders characterized by a pathologically underweight condition |
| 09/06/2001 | US20010019839 Method for production of a C1 esterase inhibitor (C1-INH)-containing composition |
| 09/06/2001 | US20010019834 Genetic engineering |
| 09/06/2001 | US20010019833 TNF receptor-specific antibodies |
| 09/06/2001 | US20010019716 Ability to enter mammalian cells and to survive within macrophages; vaccines to prevent infection by Mycobacterium tuberculosis, diagnostic assays |
| 09/06/2001 | US20010019713 Novel interleukin compositions and methods of use |
| 09/06/2001 | US20010019712 Interferon and one fatty acid moiety covalently attached to the cytokine that enhances cutaneous delivery; treating infections or enhancing an immune response |
| 09/06/2001 | DE10107360A1 Novel metalloprotease containing a thrombospondin domain (MPTS protein) is useful to treat aggrecan associated disease including rheumatoid arthritis and osteoarthritis |
| 09/06/2001 | DE10061931A1 A new nucleic acid encoding M73791 HUMNOVGENE also known as HUMQM and human RPL10 is involved in tumor suppression and useful to diagnose and treat cancer |
| 09/06/2001 | DE10008330A1 Use of NM23 polypeptide and nucleic acid, for diagnosis, prevention, and treatment of skin and intestinal diseases, and in screening for therapeutic agents |
| 09/06/2001 | DE10006889A1 Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen Use of inhibitors of caspase-3 or caspase-activated deoxyribonuclease (CAD) for the treatment of heart disease |
| 09/06/2001 | DE10006887A1 Modulators of regulatory protein RS1, useful for treating diabetes or tumors and for increasing drug transport, control concentration of transport proteins in plasma membranes |
| 09/05/2001 | EP1130394A1 In vitro models of CNS function and dysfunction |
| 09/05/2001 | EP1130122A2 Methods for the diagnosis of polymorphisms in the human EP1-R gene |
| 09/05/2001 | EP1130098A2 Mammalian osteoregulins |
| 09/05/2001 | EP1130097A1 Control of membrane traffic |
| 09/05/2001 | EP1130096A1 Proliferation arrest trancription factor (PATF) and its use |
| 09/05/2001 | EP1130095A1 Control of membrane traffic |
| 09/05/2001 | EP1130087A2 A method to identify compounds that alter the apoptotic process |
| 09/05/2001 | EP1130031A1 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
| 09/05/2001 | EP1130027A1 Memno peptides, process for preparation and use thereof |
| 09/05/2001 | EP1129728A1 Methods and compositions for the selective modification of nucleic acids |
| 09/05/2001 | EP1129724A2 Vaccines for treating colon cancer |
| 09/05/2001 | EP1129721A2 The use of isolated domains of type IV collagen to modify cell and tissue interactions |
| 09/05/2001 | EP1129720A2 Stabilized granulocyte colony stimulating factor |
| 09/05/2001 | EP1129719A1 Treatment of psoriasis through down-regulation of the EGF-receptor with topically-applied EGF |
| 09/05/2001 | EP1129718A2 Therapeutic uses of bactericidal/permeability increasing protein products |
| 09/05/2001 | EP1129717A1 Use of homologues of staphylococcal enterotoxins for cancer treatment |
| 09/05/2001 | EP1129705A1 Powder formulation for inhalation |
| 09/05/2001 | EP1129699A1 Topical compositions containing whey protein |
| 09/05/2001 | EP1129350A1 Methods for identifying modulators of bs69 activity |
| 09/05/2001 | EP1129217A2 Compositions and methods of disease diagnosis and therapy |
| 09/05/2001 | EP1129204A1 Novel system for regulating transgene expression |
| 09/05/2001 | EP1129202A2 Chlamydia antigenes and corresponding dna fragments and uses thereof |
| 09/05/2001 | EP1129201A1 Lysozyme fusion proteins in infections |
| 09/05/2001 | EP1129199A2 Cell signaling polypeptides and nucleic acids |
| 09/05/2001 | EP1129196A2 Virulence genes and proteins, and their use |
| 09/05/2001 | EP1129194A2 Interleukin-1 homolog zil1a4 |
| 09/05/2001 | EP1129193A1 Chemokine beta-7 |
| 09/05/2001 | EP1129191A1 Methods of diagnosing or treating neurological diseases |
| 09/05/2001 | EP1129190A1 Human tslp dna and polypeptides |
| 09/05/2001 | EP1129189A2 Human cell surface receptor proteins |
| 09/05/2001 | EP1129186A1 A factor viii-polypeptide with factor viii:c-activity |
| 09/05/2001 | EP1129181A2 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity |
| 09/05/2001 | EP1129177A1 Avipox vector coding an hiv antigen and a cytokine |
| 09/05/2001 | EP1129112A2 Peptides containing a cholesterol recognition sequence and their uses |
| 09/05/2001 | EP1129111A1 Methods for conversion of interferon isoforms and products thereof |
| 09/05/2001 | EP1129110A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 09/05/2001 | EP1129108A1 Caspases and apoptosis |
| 09/05/2001 | EP1129106A1 Cyclised conotoxin peptides |
| 09/05/2001 | EP1129103A1 G protein-coupled receptor resembling the leukotriene b4 receptor |
| 09/05/2001 | EP1129102A1 Gene and protein for regulation of cell death |
| 09/05/2001 | EP1128844A1 Methods for enhancing wound healing |
| 09/05/2001 | EP1128843A2 Vaccine against papillomatous digital dermatitis (pdd) |
| 09/05/2001 | EP1128842A1 Method of treating heparin-induced thrombocytopenia |
| 09/05/2001 | EP1128841A2 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders |
| 09/05/2001 | EP1128840A1 Prevention of muscle mass loss with leptin receptor ligands |
| 09/05/2001 | EP1128839A1 Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd |
| 09/05/2001 | EP1128838A1 A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5 |
| 09/05/2001 | EP1128814A1 Aerosols comprising nanoparticle drugs |
| 09/05/2001 | EP1128813A1 An inhalation system |
| 09/05/2001 | EP1128731A1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof |
| 09/05/2001 | EP1128730A1 Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the n-hydroxyanilide-type |
| 09/05/2001 | EP1067950A4 Neo-tryptophan |
| 09/05/2001 | EP0956029A4 Cyclic peptides having broad spectrum antimicrobial activity |
| 09/05/2001 | EP0826003B1 Compositions and methods for detecting and treating acquired immunodeficiency syndrome |
| 09/05/2001 | EP0792160B1 Glial derived neurotrophic factor as a neuroprotective agent |
| 09/05/2001 | EP0760677B1 A pharmaceutical preparation comprising glucagon |
| 09/05/2001 | EP0746334B1 Pharmaceutical preparation containing plasminogen activators |
| 09/05/2001 | CN1311822A Gene therapy method |
| 09/05/2001 | CN1311818A Neurotrophic factors |
| 09/05/2001 | CN1311796A Peptide antiangiogenic drugs |
| 09/05/2001 | CN1311795A Method for purification of i(Borrelia) lipoprotein OSPA |
| 09/05/2001 | CN1311794A Aerothricin analogs, their prepn. and use |
| 09/05/2001 | CN1311793A Antipicornaviral compounds, their prepn. and use |
| 09/05/2001 | CN1311693A Eosinophil chemotactic factor |
| 09/05/2001 | CN1311688A Synthetic somatostatin immunogen for growth promotion in farm animals |
| 09/05/2001 | CN1311687A Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 09/05/2001 | CN1311686A Pulmonary delivery of active agents |
| 09/05/2001 | CN1311671A Peptidyl-prolyl i-(cis)-trans isomerase inhitors and uses thereof |
| 09/05/2001 | CN1311666A Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
| 09/05/2001 | CN1311332A Producing erythrocyte irritable factor/granulocyte colony irritable factor fusion protein by genetic engineering method |
| 09/05/2001 | CN1311329A New polypeptide-human phosphomannose isomerase 16 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311327A New polypeptide-human cathepsin 18 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311326A New polypeptide-human RNA unwindase 15 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311325A New polypeptide-human RNA unwindase 12 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311324A New polypeptide-human RNA unwindase 105 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311323A New polypeptide-formamidopyrimidine-DNA glycosylase 37 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311322A New polypeptide-human reverse transcriptase 13 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311321A New polypeptide-human vacuole-adnosine triphosphatase C subunit 23 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311320A New polypeptide-human protein tyrosine phosphorylase 15 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311318A New polypeptide-human phospho-esterase c protein 65 and polynucleotide for coding polypeptide |
| 09/05/2001 | CN1311316A New polypeptide-mouse soluble adenylate cyclase 25 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311314A New polypeptide-human ribosome S6 serine-threonine protein kinase 10 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311312A New polypeptide-human protein kinase TAK 1-27 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311311A New polypeptide-human phosphorylase kinase 18 and polynucleotide for coding such polypeptide |
| 09/05/2001 | CN1311310A New polypeptide-human glucokinase 41 and polynucleotide for coding such polypeptide |